Avidity Biosciences Inc
Change company Symbol lookup
Select an option...
RNA Avidity Biosciences Inc
AVA Avista Corp
DKNG DraftKings Inc
ADXN Addex Therapeutics Ltd
SSU SIGNA Sports United NV
RVIV Reviv3 Procare Co
BJDX Bluejay Diagnostics Inc
SHYMF Nala Digital Commerce Ltd
PM Philip Morris International Inc
EPAC Enerpac Tool Group Corp

Health Care : Biotechnology | Small Cap Value
Company profile

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs.). The Company's AOC platform is designed to combine the specificity of monoclonal antibodies (mAbs), with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with RNA therapeutics. The AOC platform also has the option to deploy various types of oligonucleotides, including small interfering RNA (siRNAs) and patient measure of safety (PMOs), whose specific mechanisms of action modify RNA function in different ways. The Company's pipeline includes AOC 1001, and AOC 1020. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1). AOC 1020 is designed to treat people living with facioscapulohumeral.

Day's Change
-0.17 (-2.41%)
B/A Size
Day's High
Day's Low

Today's volume of 32,405 shares is on pace to be much lighter than RNA's 10-day average volume of 1,272,457 shares.


Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.